Personal Information
Entreprise/Lieu de travail
Greater New York City Area, New York United States
Profession
CEO at Brand Acumen, Keynote Speaker and Lecturer
Secteur d’activité
Advertising / Marketing / PR
Site Web
www.brandacumenstudios.com
À propos
I have a dual role as the CEO and Founder of Brand Acumen, the world leader in brand name development, and Chairman and managing Director at Harrison Hayes, a Life Science Venture Capital Firm.
Currently, I am participating as a Key Innovation Leader on a special panel established to shape both FDA and FTC governance on the controversial naming of Biosimilars and the draft guidance documents associated with this topic.
Unfortunately, I was unable to compete in the brand creation business for several years due to the fact that I was the Founder and Chairman of Addison Whitney which was sold to InVentiv Health, (and of course, confined to a non-compete agreement for five years which pre...
Mots-clés
brand acumen
branding
bill smith brand acumen
bill smith ceo brand acumen
name development
naming
brand name
drug naming
fda
pharmaceutical naming
pharmaceutical brand names
fda guidance
brand symbol
drug names
pharmaceutical names
pharmaceuticals
cder
brand institute
brand acumen. the global leader in pharmaceutical
billjsmith
brand management
brand
havas
brands
brand acumen studios
drugs
new product name
bil smith ceo
harrison hayes
orphan drugs
ema
fda naming guidance
inn
regulatory
health canada
bill smith ceo
interbrand
dmepa
identity
bill smith
addison whitney
drugs regulatory inn usan
#brandacumen #brandstandards
#brandacumen #beer #ideation
#brandacumen
branding new marketing naming
innovation
cosmetics
brand standards
rare disease
orphanetics
european medicines agency
drug name submission
pharnacovigilance
biosimilars naming naming drugs billjsmith linkedi
fda advisor
bi
biosimilars
naming safety
dmepa naming guidance
cder naming guidance
usan
non-proprietary names
havas ceo bill smith
na
havas ceo
juno therapeutics
bellicum
car-t
cellectis
novartis
kite pharma
medical affairs
name submission
approvals
clinical
ceo brand acumen
bil smith ceo brand acumen
lantus
sanofi
corporate identity
medical
acumen
gene therapy
nomenclature
automotive
autoweek
david carson
billsmith
car names
cancer
adc
Tout plus
Présentations
(16)Documents
(19)J’aime
(1)Zarxio: The FDA's CDER Proprietary Name Review of the First FDA Approved Biosimilar.
Bill Smith
•
il y a 8 ans
Personal Information
Entreprise/Lieu de travail
Greater New York City Area, New York United States
Profession
CEO at Brand Acumen, Keynote Speaker and Lecturer
Secteur d’activité
Advertising / Marketing / PR
Site Web
www.brandacumenstudios.com
À propos
I have a dual role as the CEO and Founder of Brand Acumen, the world leader in brand name development, and Chairman and managing Director at Harrison Hayes, a Life Science Venture Capital Firm.
Currently, I am participating as a Key Innovation Leader on a special panel established to shape both FDA and FTC governance on the controversial naming of Biosimilars and the draft guidance documents associated with this topic.
Unfortunately, I was unable to compete in the brand creation business for several years due to the fact that I was the Founder and Chairman of Addison Whitney which was sold to InVentiv Health, (and of course, confined to a non-compete agreement for five years which pre...
Mots-clés
brand acumen
branding
bill smith brand acumen
bill smith ceo brand acumen
name development
naming
brand name
drug naming
fda
pharmaceutical naming
pharmaceutical brand names
fda guidance
brand symbol
drug names
pharmaceutical names
pharmaceuticals
cder
brand institute
brand acumen. the global leader in pharmaceutical
billjsmith
brand management
brand
havas
brands
brand acumen studios
drugs
new product name
bil smith ceo
harrison hayes
orphan drugs
ema
fda naming guidance
inn
regulatory
health canada
bill smith ceo
interbrand
dmepa
identity
bill smith
addison whitney
drugs regulatory inn usan
#brandacumen #brandstandards
#brandacumen #beer #ideation
#brandacumen
branding new marketing naming
innovation
cosmetics
brand standards
rare disease
orphanetics
european medicines agency
drug name submission
pharnacovigilance
biosimilars naming naming drugs billjsmith linkedi
fda advisor
bi
biosimilars
naming safety
dmepa naming guidance
cder naming guidance
usan
non-proprietary names
havas ceo bill smith
na
havas ceo
juno therapeutics
bellicum
car-t
cellectis
novartis
kite pharma
medical affairs
name submission
approvals
clinical
ceo brand acumen
bil smith ceo brand acumen
lantus
sanofi
corporate identity
medical
acumen
gene therapy
nomenclature
automotive
autoweek
david carson
billsmith
car names
cancer
adc
Tout plus